Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
AQST compared with AZN: revenue, margins and what each company keeps, and the suppliers and customers both name
AQST
Aquestive Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
AZN
Astrazeneca PLC
Change
Mkt cap
Revenue
Revenue
vs
Compare
AQST
Aquestive Therapeutics, Inc.
vs
AZN
Astrazeneca PLC
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
AQST, solid
AZN, dashed
Supply-chain overlap
Revenue flow
AQST: latest quarter is a loss; flow not drawable. AZN: latest quarter not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only AQST
12
INDV
Indivior
customer
—
Licensees
unlisted
customer
—
RTW Investments
unlisted
customer
—
Sunovion
unlisted
customer
8 more · AQST chain
›
Shared
0
No shared counterparties.
Only AZN
20
ARQT
Arcutis Biotherapeutics
customer
GRAL
Grail
supplier
RCUS
Arcus Biosciences
customer
NKTR
Nektar Therapeutics
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
16 more · AZN chain
›
AQST
Aquestive Therapeutics, Inc.
Change
3.89
▼
−3.79%
· post 3.92
Mkt cap
$488.2M
Revenue
$14M
Q2 FY26
Revenue
$45M
FY25
AZN
Astrazeneca PLC
Change
186.63
▲
+7.01%
· post 186.35
Closed
Oct 30 '26
Mkt cap
$289.5B
Revenue
—
Revenue
—
vs
Compare
Closed
Oct 30 '26
AQST
Aquestive Therapeutics, Inc.
vs
AZN
Astrazeneca PLC
3.89
▼
−3.79%
post 3.92
Price
186.63
▲
+7.01%
post 186.35
$488.2M
Mkt cap
$289.5B
Q2 FY26
$14M
Revenue
—
FY25
$45M
Revenue
—
Change
Change
AQST
3.89
▼
−3.79%
vs
AZN
186.63
▲
+7.01%
Closed
Oct 30 '26